Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers
Open Access
- 1 June 2021
- journal article
- review article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 13 (6) , 3846-3864
Abstract
Medication non-adherence to asthma and chronic obstructive pulmonary disease therapy poses a significant burden for patients and societies. Non-adherence encompasses poor initiation, implementation (including poor inhalation technique) and non-persistence. Globally, non-adherence is associated with poor clinical outcomes, reduced quality of life and high healthcare and societal costs. Costs are mainly caused by excess hospitalizations and impaired work productivity. Multiple intervention programs to increase adherence in patients with asthma and chronic obstructive pulmonary disease have been conducted. However, these intervention programs are generally not as effective as intended. Additionally, adherence outcomes are mostly examined with non-objective or non-granular measures (e.g., self-report, dose count, pharmacy records). Recently developed smart inhalers could be the key to objectively diagnose and manage non-adherence effectively in patients with asthma and chronic obstructive pulmonary disease. Smart inhalers register usage of the inhaler, record time and date, send reminders, give feedback about adherence and some are able to assess inhaler technique and predict exacerbations. Still, some limitations need to be overcome before smart inhalers can be incorporated in usual care. For example, their cost-effectiveness and budget impact need to be examined. It is likely that smart inhalers are particularly cost-effective in specific asthma and chronic obstructive pulmonary disease subgroups, including patients with asthma eligible for additional GINA-5 therapy (oral corticosteroids or biologics), patients with severe asthma in GINA-5, patients with asthma with short-acting beta2 agonists overuse, patients with asthma and chronic obstructive pulmonary disease with frequent exacerbations and patients with asthma and chronic obstructive pulmonary disease of working-age. While there is high potential and evidence is accumulating, a final push seems needed to cost-effectively integrate smart inhalers in the daily management of patients with asthma and chronic obstructive pulmonary disease.Keywords
This publication has 98 references indexed in Scilit:
- Association of Chronic Obstructive Pulmonary Disease Maintenance Medication Adherence With All-Cause Hospitalization and Spending in a Medicare PopulationThe American Journal of Geriatric Pharmacotherapy, 2012
- A Large Subgroup of Mild-to-Moderate Asthma Is Persistently NoneosinophilicAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherenceJournal of Allergy and Clinical Immunology, 2011
- Problem solving to improve adherence and asthma outcomes in urban adults with moderate or severe asthma: A randomized controlled trialJournal of Allergy and Clinical Immunology, 2011
- Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physiciansInternational Journal of Chronic Obstructive Pulmonary Disease, 2011
- Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costsRespiratory Medicine, 2010
- Shared Treatment Decision Making Improves Adherence and Outcomes in Poorly Controlled AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2010
- The Impact of a Program for Control of Asthma in a Low-Income SettingWorld Allergy Organization Journal, 2010
- Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherenceAnnals of Allergy, Asthma & Immunology, 2003
- Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango)Social Science & Medicine, 1997